Core Viewpoint - Siemens Group has announced a significant equity restructuring plan, transferring approximately 30% of its stake in Siemens Healthineers to its shareholders, valued at €33.5 billion [1][3]. Group 1: Equity Restructuring - Prior to the restructuring, Siemens held 67% of Siemens Healthineers, which will decrease to below 37% after the transfer [3]. - The CEO of Siemens, Roland Busch, indicated plans to further reduce the stake to below 20% in the medium term, with potential for additional divestitures before the current plan is approved [3]. - The restructuring plan requires approval from shareholders, as well as regulatory bodies in the EU and the US, with an expected completion in the second quarter of 2026 [3]. Group 2: Business Background - Siemens Healthineers has a history dating back to the late 19th century and was independently listed in 2018 with Siemens initially holding 85% [3]. - The company has strengthened its market position through strategic acquisitions, including the €13.9 billion purchase of Varian, a US radiation therapy giant, in 2020, maintaining a current market value of approximately €52 billion [3]. Group 3: Management Changes - Siemens announced that CFO Ralf Thomas will step down in the 2026 fiscal year, with the position being taken over by Veronika Bienert, the CEO of Siemens Financial Services [3]. - After stepping down, Thomas will continue to serve as a member of the supervisory board of Siemens Healthineers to ensure business continuity [3].

（来源：一度医药） 转自：一度医药 西门子医疗CEO Bernd Montag表示："我们赞赏这一明确决策，这将延续我们迈向全面独立公司的发展 进程。" 市场分析认为，股权不确定性的消除有望显著提振西门子医疗的股价表现。 不过，本次拆分计划仍需满足多项前提条件：包括西门子股东、西门子医疗投资者的批准（可能需要召 开特别股东大会），以及德国税务部门的审核通过。 相较于实物股息分配的方式，本次拆分方案在税务层面更具优势，分析师指出，若采用股息分配可能会 产生巨额税务支出，而目前的方案更符合双方利益。Busch对此信心十足，直言"计划必将落地"。 11月12日，路透社消息，德国工业巨头西门子（SIEGn.DE）宣布重大股权调整计划：将通过向自身股 东划转股份的方式，减持其在医疗设备制造商西门子医疗（Siemens Healthineers，SHLG.DE）的持股， 涉及股权价值达335亿欧元（约合390.7亿美元）。这一举措不仅将重塑两家公司的股权结构，更标志着 西门子医疗向全面独立运营迈出关键一步。 根据公告，西门子目前持有西门子医疗67%的股份，此次将直接划转30%的股权给自身股东，减持后持 股比例将降至37% ...

Group 1 - The company acquired 1.50% of unfulfilled equity in Buchang Pharmaceutical's subsidiary, Buchang Cosmetics, from Zhao Lu for 0 yuan, while Zhao Lu transferred the remaining equity: 1.00% to Xie Jihui and 0.50% to Wang Qi, also for 0 yuan [2] - Before the transaction, the shareholding structure was: Buchang Pharmaceutical 94.00%, Chen Gongming 3.00%, Zhao Lu 3.00%. After the transaction, the structure changed to: Buchang Pharmaceutical 94.50%, Chen Gongming 3.00%, Xie Jihui 2.00%, Wang Qi 0.50% [2] - Buchang Cosmetics was established in May 2024 with a registered capital of 10 million yuan. As of the first half of 2025, it reported a net asset of -45,100 yuan, revenue of 0 yuan, and a net profit of -29,300 yuan [2] Group 2 - The transaction does not constitute a related party transaction or a major asset restructuring [2] - The transaction does not change the scope of consolidation in the financial statements [2] - There is no significant adverse impact on the company's financial condition and operating results [2]

证券代码：000932 股票简称：华菱钢铁 公告编号：2025-38 湖南华菱钢铁股份有限公司 本公司董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导性陈述 或重大遗漏。 一、董事会会议召开情况 湖南华菱钢铁股份有限公司（以下简称"公司"或"华菱钢铁"）第八届董事会第三十 三次会议于 2025 年 6 月 3 日以通讯表决方式召开，会议通知已于 2025 年 5 月 26 日发 出。会议发出表决票 9 份，收到表决票 9 份。本次会议的召开符合《公司法》《证券法》 和《公司章程》的有关规定。 二、董事会会议审议情况 为促进子公司深圳华菱商业保理有限公司（以下简称"华菱保理"）业务拓展，加 强其与公司下属核心钢厂的业务协同，更好地服务钢铁主业，增强核心钢厂竞争力，公 司对华菱保理股权进行调整，即华菱钢铁将所持华菱保理 51%股权转让给下属 4 家核 心钢铁控股子公司湖南华菱湘潭钢铁有限公司（以下简称"华菱湘钢"）、湖南华菱涟 源钢铁有限公司（以下简称"华菱涟钢"）、衡阳华菱钢管有限公司（以下简称"华菱 衡钢"）和阳春新钢铁有限责任公司（以下简称"阳春新钢铁"），华菱湘钢、华菱涟 钢、华菱衡钢 ...